These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 35879147)

  • 1. Perioperative Hemostatic Management of a Newborn With Hereditary Hemophilia A Undergoing Emergent Surgery for Dextro-Transposition of the Great Arteries.
    Torfs A; Chardonnal L; Meunier S; Désage S; Henaine R; Lilot M
    J Cardiothorac Vasc Anesth; 2022 Oct; 36(10):3855-3858. PubMed ID: 35879147
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Perioperative continuous infusions of factor VIII versus factor IX for patients with hemophilia A or B undergoing major surgery.
    Tse B; Nisenbaum R; Floros G; Jiwajee A; Teitel J; Sholzberg M
    J Thromb Thrombolysis; 2023 Feb; 55(2):273-281. PubMed ID: 36547766
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Surgical evaluation of a recombinant factor VIII prepared using a plasma/albumin-free method: efficacy and safety of Advate in previously treated patients.
    Négrier C; Shapiro A; Berntorp E; Pabinger I; Tarantino M; Retzios A; Schroth P; Ewenstein B
    Thromb Haemost; 2008 Aug; 100(2):217-23. PubMed ID: 18690340
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FVIII replacement in 12-day-old newborn with haemophilia A requiring surgical repair of D transposition of great arteries.
    Kuzmanovic M; Stajevic M; Vukomanovic V; Serbic O; Jankovic B
    Haemophilia; 2011 Sep; 17(5):821-2. PubMed ID: 21435118
    [No Abstract]   [Full Text] [Related]  

  • 5. Continuous infusions of B domain-truncated recombinant factor VIII, turoctocog alfa, for orthopedic surgery in severe hemophilia A: first case report.
    Takeyama M; Nogami K; Kobayashi R; Ogiwara K; Taniguchi A; Nakanishi Y; Inagaki Y; Tanaka Y; Shima M
    Int J Hematol; 2018 Aug; 108(2):199-202. PubMed ID: 29383626
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Perioperative safety and hemostatic efficacy of Advate
    Nogami K; Takedani H; Shima M; Yoshioka A; Matsushita T; Takamatsu J; Taki M; Fukutake K; Uchikawa H; Takagi H; Arai M; Engl W; Shirahata A
    Int J Hematol; 2018 Jul; 108(1):22-29. PubMed ID: 29594923
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Peri-cardiac surgery coagulation management in a severe hemophilia A patient: A case report.
    Xu H; Henry D; Li C; Zhao H; Yang Y
    Medicine (Baltimore); 2019 Jun; 98(24):e15897. PubMed ID: 31192923
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The "OPTI-CLOT" trial. A randomised controlled trial on periOperative PharmacokineTIc-guided dosing of CLOTting factor concentrate in haemophilia A.
    Hazendonk HC; van Moort I; Fijnvandraat K; Kruip MJ; Laros-van Gorkom BA; van der Meer FJ; Meijer K; Peters M; Schutgens RE; Zwaan CM; Driessens MH; Polinder S; Leebeek FW; Mathôt RA; Cnossen MH
    Thromb Haemost; 2015 Aug; 114(3):639-44. PubMed ID: 26062822
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Continuous Infusion of Factor VIII and von Willebrand Factor in Surgery: Trials with pdFVIII LFB or pdVWF LFB in Patients with Bleeding Disorders.
    Windyga J; Guillet B; Rugeri L; Fournel A; Stefanska-Windyga E; Chamouard V; Pujol S; Henriet C; Bridey F; Négrier C
    Thromb Haemost; 2022 Aug; 122(8):1304-1313. PubMed ID: 35642281
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination of hemostatic therapies for treatment of patients with hemophilia A and inhibitors.
    Livnat T; Budnik I; Levy-Mendelovich S; Avishai E; Misgav M; Barg AA; Lubetsky A; Brutman-Barazani T; Kenet G
    Blood Cells Mol Dis; 2017 Jul; 66():1-5. PubMed ID: 28689155
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Liver transplantation in hemophilia A and von Willebrand disease type 3: perioperative management and post-transplant outcome.
    Alonso Madrigal C; Dobón Rebollo M; Laredo de la Torre V; Palomera Bernal L; García Gil FA
    Rev Esp Enferm Dig; 2018 Aug; 110(8):522-526. PubMed ID: 29931985
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetic analysis of anti-hemophilic factor in the obese patient.
    Graham A; Jaworski K
    Haemophilia; 2014 Mar; 20(2):226-9. PubMed ID: 24252161
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Soy phosphatidylinositol containing nanoparticle prolongs hemostatic activity of B-domain deleted factor VIII in hemophilia A mice.
    Shetty KA; Kosloski MP; Mager DE; Balu-Iyer SV
    J Pharm Sci; 2015 Feb; 104(2):388-95. PubMed ID: 24700333
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transposition of the Great Arteries-Are We Doing Better? Correlating Outcome to Change in Renal Function Over 2 Decades of Arterial Switch Operation.
    Shostak E; Dagan O; Hosh G; Amir G; Frenkel G; Schiller O
    Pediatr Crit Care Med; 2020 Sep; 21(9):e782-e788. PubMed ID: 32433443
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Management of hemophilia A and B during surgical correction of transposition of the great arteries.
    Roskos RR; Gilchrist GS; Kazmier FJ; Feldt RH; Danielson GK
    Mayo Clin Proc; 1983 Mar; 58(3):182-6. PubMed ID: 6827862
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of continuous infusion versus bolus injection of factor concentrates for blood management after total knee arthroplasty in patients with hemophilia.
    Park YS; Shin WJ; Kim KI
    BMC Musculoskelet Disord; 2017 Aug; 18(1):356. PubMed ID: 28830476
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low-dose continuous infusion of factor VIII in patients with haemophilia A.
    Prelog T; Dolničar MB; Kitanovski L
    Blood Transfus; 2016 Sep; 14(5):474-80. PubMed ID: 26674820
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bleeding management: rFVIIIFc in hemophilia A and liver transplantation.
    Grottke O; Rieg A; Ulmer F; Hein M
    Anaesthesiologie; 2023 Dec; 72(12):883-886. PubMed ID: 37563315
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk of bleeding and inhibitor development after circumcision of previously untreated or minimally treated severe hemophilia A children.
    Elalfy MS; Elbarbary NS; Eldebeiky MS; El Danasoury AS
    Pediatr Hematol Oncol; 2012 Aug; 29(5):485-93. PubMed ID: 22866674
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Global hemostatic assay of different target procoagulant activities of factor VIII and factor IX.
    Yoo KY; Jung SY; Hwang SH; Lee SM; Park JH; Nam HJ
    Blood Res; 2018 Mar; 53(1):41-48. PubMed ID: 29662861
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.